$SUPN News
Last published 1w ago
- 1w agoSUPNSupernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical LeaderGlobeNewswireMerger positions Supernus as a leading diversified central nervous system (CNS) biopharmaceutical company with a broad portfolio of marketed medicines, enhanced financial flexibility and a differentiated
- 1w agoSUPNSupernus Pharmaceuticals 3Q 2026 Financial and Business Update Conference Call - SUPERNUS PHARMACEUTICALS INCEarnings Call TranscriptsGood afternoon, and thank you for standing by. Welcome to the Superdness Pharmaceutical Third Quarter 2026 Financial Results Conference Call. At this time, all participants are in listen-only mode. After the speaker's pr
- 1w agoSUPNSUPERNUS PHARMACEUTICALS, INC. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoSUPNSupernus Announces Third Quarter 2026 Financial ResultsGlobeNewswireRecord total revenues of $226.8 million in the third quarter 2026, an 18% increase compared to same period last year.Combined revenues of the Company's four growth products increased to $192.2 million in the third
- 2w agoSPGIHURNINDVSUPNUpdated Effective Date: Huron Consulting Group Set to Join S&P SmallCap 600PR NewswireNEW YORK, Oct. 28, 2026 /PRNewswire/ -- Huron Consulting Group Inc. (NASD: HURN) will replace Supernus Pharmaceuticals Inc. (NASD: SUPN) in the S&P SmallCap 600 before the opening of trading on Tuesday, November 3,
- 2w agoSUPNChloe Kim Is Changing the Conversation Around ADHD in Women with Qelbree® for ‘Ms. Represented’ CampaignGlobeNewswireThe ‘Ms. Represented’ campaign expands its reach with professional snowboarder Chloe Kim, who shares her ADHD experience to help connect with a younger generation of women.More than 60% of U.S. women who reported ever
- 2w agoSPGIHURNINDVSUPN+4MSG Rangers and Huron Consulting Group Set to Join S&P SmallCap 600PR NewswireNEW YORK, Oct. 22, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600: MSG Rangers Inc. (NYSE:MSGR) will be added to the S&P SmallCap 600 effective prior to
- 3w agoSUPNSupernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)GlobeNewswireOrphan-drug exclusivity provides seven years of market exclusivity for ONAPGO Additionally, the Company submitted an sNDA to the FDA for a second supplier for ONAPGO, with potential approval by mid-year 2027
- 3w agoSUPNSupernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026GlobeNewswireROCKVILLE, Md., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous
- 2mo agoSUPNWells Fargo 21st Annual Healthcare Conference - SUPERNUS PHARMACEUTICALS INCEarnings Call TranscriptsGood afternoon, ladies and gentlemen. I'm Rahul Sood, Managing Director in the Healthcare Investment Banking Group at Wells Fargo. I have the pleasure of hosting Jack Kattar, CEO of Supernus Pharmaceuticals. Jack, welcom
- 2mo agoSUPNSupernus Pharmaceuticals to Participate in September Investor ConferencesGlobeNewswireROCKVILLE, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous
- 2mo agoSUPNChloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHDGlobeNewswireChloe Kim is partnering with Supernus to highlight the importance of recognizing ADHD in adults and help empower individuals to work with their doctors to develop a tailored treatment plan.While ADHD is often associated
- 3mo agoSUPNSupernus Announces Second Quarter 2026 Financial ResultsGlobeNewswireTotal revenues were $219.1 million in the second quarter 2026, a 32% increase compared to same period last year. Combined revenues of the Company's four growth products increased to $175.7 million in the second
- 3mo agoSUPNINDVSupernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant ScaleGlobeNewswireCombines highly complementary businesses, with a diversified portfolio of CNS medicines totaling approximately $2.2 billion in combined annual revenuesEnhanced financial position and free cash flow generation enabling
- 3mo agoSUPNSupernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026GlobeNewswireROCKVILLE, Md., July 22, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous
- 4mo agoSUPNSupernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHDGlobeNewswireQelbree remains the first novel, non-stimulant ADHD medication approved in over a decade and is the only ADHD treatment with serotonin (5-HT2C) pharmacodynamics approved in its FDA product labeling.Qelbree has provided
- 4mo agoSUPNSupernus Expands Partnership With MERGE as AI-Powered Agency of RecordGlobeNewswireCHICAGO, June 17, 2026 (GLOBE NEWSWIRE) -- MERGE announces its selection as the Agency of Record (AOR) for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a dynamic biopharmaceutical company dedicated to developing
- 5mo agoSUPNSupernus Pharmaceuticals, Inc. at Jefferies Global Healthcare Conference in New York - SUPERNUS PHARMACEUTICALS INCEarnings Call TranscriptsAndrew Tsai, Senior Biotech Analyst, Jefferies, USA Okay. We're going to get started with our next session. I'm Andrew Tsia, Senior Bio-tech Analyst at Jefferies. And it's my pleasure to have Jack Kattar, CEO of Sopranos
- 5mo agoSUPNSupernus Pharmaceuticals to Participate in June Investor ConferencesGlobeNewswireROCKVILLE, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system
- 6mo agoSUPNSupernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care ConferenceGlobeNewswireROCKVILLE, Md., May 06, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system
- 6mo agoSUPNSupernus Announces First Quarter 2026 Financial ResultsGlobeNewswireTotal revenues were $207.7 million in the first quarter 2026, a 39% increase compared to same period last year.Combined revenues of the Company's four growth products increased to $149.1 million in the first quarter
- 6mo agoSUPNSupernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026GlobeNewswireROCKVILLE, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous
- 6mo agoACOGKALVSUPNAlpha Cognition Strengthens Its Board of Directors with Appointment of Bethany SensenigBusiness WireAlpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment
- 8mo agoSUPNSupernus Announces Record Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswireRecord total revenues of $211.6 million and $719.0 million in the fourth quarter and full year 2025, a 21% and 9% increase compared to same periods last year. Combined revenues of the Company's four growth products
- 8mo agoSUPNSupernus Pharmaceuticals to Participate in March Investor ConferencesGlobeNewswireROCKVILLE, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system
- 8mo agoARWRJNJMGTXOTLC+1Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&AGlobeNewswireAUSTIN, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage
- 9mo agoSUPNSupernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026GlobeNewswireROCKVILLE, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system
- 9mo agoSUPNLunai Bioworks, Inc. Issues Letter to ShareholdersPR NewswireDear Shareholders, We have completed our AI platform in the last 12 months and now it is commercial. Negotiations are moving forward with several...
- 11mo agoSUPNSupernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual ConferenceGlobeNewswireROCKVILLE, Md., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system
- 11mo agoSUPNSupernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswireROCKVILLE, Md., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system
- 12mo agoSUPNSupernus to Participate in the 2025 Jefferies Global Healthcare Conference in LondonGlobeNewswireROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system
- 1y agoSUPNSupernus Announces Third Quarter 2025 Financial ResultsGlobeNewswireCombined revenues of the Company's four growth products increased 52% to $149.2 million in the third quarter of 2025, compared to the same period in 2024. This strong growth was driven by an increase in net sales of
- 1y agoSUPNSupernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025GlobeNewswireROCKVILLE, Md., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system
- 1y agoBIIBSUPNBiogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in EuropeGlobeNewswirePostpartum depression is a leading cause of maternal mortality in Europe1-2, and is one of the most common medical conditions associated with pregnancy3-5; up to 20% of women experience postpartum depressive
- 1y agoSUPNSupernus Pharmaceuticals to Participate in September Investor ConferencesGlobeNewswireROCKVILLE, Md., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system
- 1y agoSUPNSupernus Pharmaceuticals, Inc. (SUPN) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoSUPNSupernus Announces Second Quarter 2025 Financial ResultsGlobeNewswireNet sales of Qelbree® increased 31% in the second quarter of 2025, compared to the same period in 2024. Net sales of Qelbree of $77.6 million and $142.3 million in the second quarter and first six months of 2025,
- 1y agoSAGESUPNSupernus Pharmaceuticals Completes Acquisition of Sage TherapeuticsGlobeNewswireROCKVILLE, Md., July 31, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) ("Supernus") today announced that it has successfully completed its previously announced acquisition of Sage Therapeutics,
- 1y agoSAGESUPNSupernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender OfferGlobeNewswireROCKVILLE, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc., a Delaware corporation (NASDAQ:SUPN) ("Supernus", and the "Company"), today announced that the required waiting period
- 1y agoSUPNSupernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025GlobeNewswireROCKVILLE, Md., July 22, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system
- 1y agoSAGESUPNSupernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product PortfolioGlobeNewswireProposed acquisition expected to accelerate mid- to long-term revenue and cash flow growth and further diversify revenue base.Strengthens Supernus' leading presence in neuropsychiatric conditions with an innovative
- 1y agoSUPNJay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus PharmaceuticalsGlobeNewswireROCKVILLE, Md., May 29, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals is expanding its partnership with TV personality and sports reporter Jay Glazer in a new content series featuring his wife, Rosie Glazer. The
- 1y agoSUPNSupernus Announces Paragraph IV ANDA Filings for Qelbree®GlobeNewswireROCKVILLE, Md., May 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system
- 1y agoSUPNSupernus to Participate in the 2025 Jefferies Global Healthcare ConferenceGlobeNewswireROCKVILLE, Md., May 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system
- 1y agoSUPNBusy Philipps Empowers Women with ADHD to Go from Feeling Misrepresented to Being 'Ms. Represented' in First-of-its-Kind Campaign with Supernus PharmaceuticalsGlobeNewswireFemales with ADHD frequently present with inattentive symptoms, which can be more difficult to recognize than the hyperactive and impulsive symptoms more often seen in malesBoys are two times more likely to be diagnosed
- 1y agoSUPNSupernus Announces First Quarter 2025 Financial ResultsGlobeNewswireFirst quarter 2025 net sales of Qelbree® increased 44% to $64.7 million, compared to the same period in 2024.First quarter 2025 net sales of GOCOVRI® increased 16% to $30.7 million, compared to the same period
- 1y agoSUPNSupernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025GlobeNewswireROCKVILLE, Md., April 23, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous
- 1y agoSUPNSupernus Pharmaceuticals, Inc. - Appeal, Affirmed with New Ground of RejectionUS Patent Trial and Appeal Board
- 1y agoSUPNSupernus to Participate in Two Upcoming Investor ConferencesGlobeNewswireROCKVILLE, Md., March 04, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous
- 1y agoSUPNSupernus to Participate in the TD Cowen 45th Annual Health Care ConferenceGlobeNewswireROCKVILLE, Md., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system